NCT07655180Phase 3Recruiting

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-08Estimated

Enrollment · participants210Estimated

Source updated2026-06-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID-19

Treatments or interventions studied

COVID-19 mRNA vaccineDrug
VYD2311Drug
Placebo (Normal Saline)Drug

Primary outcomes · main study measures

Read the study measures

measure: Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6; timeFrame: Through 6 days after dose; measure: Assessment of systemic reactions solicited via e-diary through day 6; description: To compare the systemic reaction of VYD2311 (study drug) with a COVID-19 vaccine when administered alone or concurrently in healthy adults. E-diaries will solicit participant reported systemic reactions including vomiting, fever, diarrhea, headache, fatigue, chills, myalgia, and arthralgia.; timeFrame: Through 6 days after dose

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history